To compare the risk of unplanned hospitalization in high-care nursing home residents taking Beers potentially inappropriate medications (PIMs) against that of other elderly.
Introduction
Older people are generally more susceptible to adverse drug events due to physiological deterioration, polypharmacy and other age-related factors. [1] [2] [3] This has led to the development of lists of 'potentially inappropriate medications' (PIMs) to be avoided in the elderly, such as the Beers Criteria. 4 Numerous studies have examined the prevalence of PIMs in elderly populations, while others have concentrated on the association between PIMs and adverse health outcomes. However, little is known on whether nursing home residents are at greater risk of PIM-related adverse events than other elderly people. Due to poor health, nursing home residents may have a greater predisposition to medication exposure (including PIMs) and to serious outcomes such as unplanned hospitalizations. However, close monitoring by aged care staff may help protect nursing home residents from serious PIM-related harm.
Our large population-based study (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) examined the association between exposure to Beers medications 4 
and unplanned hospitalizations in
Western Australian (WA) residents aged ≥65 years. It compared estimates applicable to high-care nursing home residents with those of other WA elderly based on exposure to general PIMs upon hospitalization (dichotomous measure), number of different PIMs taken, and overall PIM quantity consumed over three months.
Methods

Data linkage and cohort selection
This study linked Australian Pharmaceutical Benefits Scheme (PBS), 5, 6 Medicare 7,8 and residential aged care 9 data with inpatient, death and electoral roll records from the WA Data Linkage System 10 through probabilistic linkage.
The study protocol was approved by The University of Western Australia's Human Research Ethics Committee.
The cohort was restricted to people aged ≥65 years by the end of 2004, who continuously resided in WA during 1993-2005 (until death) and had ≥1 pharmaceutical claim during that time, thus ensuring that study participants had ascertainable drug exposures. Eight percent were subsequently excluded due to problem data (e.g. records post-death, no gender on any record). The resulting cohort captured 80-85% of WA elderly residents.
Drug reference database
Details of all PBS items from available schedules (August 1991-June 2007) 11 were assembled into a reference database, retaining the last published entry for each item. Anatomical Therapeutic Chemical (ATC) codes were reconciled with the 2007 World Health Organization (WHO) ATC drug classification. 12 Since the prescribed dose was not recorded on PBS claims, average prescribed daily doses from the Australian Bettering the Evaluation and Care of Health (BEACH) 13 general practice data, MIMS Australia 14 registered drug information, and 2008 WHO ATC Defined Daily Doses (DDDs) 15 were compared to derive average daily doses for each item, based on drug form, route and strength.
Furthermore, each drug's elimination half-life was obtained (predominantly from MIMS), 14 from which the period of drug effect, defined as five times the drug's half-life, 16, 17 was estimated.
Drug groups and domains
Each item from the 2003 Beers list 4 was defined according to the 2007 ATC classification. 12 Following integration of patient and drug reference variables with the PBS master data file for 1993-2005, the ATC code list for 'general' PIMs (i.e. excluding disease-specific criteria) was applied to determine which of these PIMs were supplied to WA residents aged ≥65 years during the study period. This process identified 43 individual PIMs, which were grouped into 20 broad drug classes (i.e. drug domains), each class consisting of medications used to treat similar conditions to those treated by related PIMs.
Case-time-control design
The relationship between PIM exposure and unplanned hospitalizations was expressed as an odds ratio (OR) obtained from an enhanced case-time-control design. 18, 19 This involved index subjects acting both as cases and as their own historical controls, while background time trends in predisposition to exposure were adjusted using similarly constructed case and control observation windows Once created, the case and control time records for index and reference subjects were populated with variables required to control for potential confounding, including nursing home status at the specific time stated on the record (i.e. case or control time); hospital days, overall Charlson comorbidity index 20 and 'general practitioner (GP) coverage' percentage, all for the previous year; and a drug consumption profile for the preceding 90 days (plus the case or control date), which included the number of broad medication categories involved, the overall number of daily doses consumed (for any drug) and a count of daily doses for each broad drug category. To determine the GP coverage percentage, each GP visit identified in the Medicare dataset was allocated a 'coverage' period of 61 days (overlapping periods merged together), from which coverage proportions were calculated for the period of interest. This measure provided a general indicator of patients' ongoing GP monitoring.
Additionally, PBS records were checked to ascertain exposure status at each case and control date. If a prescription was found for a PIM and the time period bound by its supply date and exposure effect end date overlapped with the case or control time, the PIM exposure status was set to 'exposed'. The end date was calculated by adding the prescription's number of drug consumption days (i.e. script's drug quantity / average daily dose) to the supply date (-1) plus the period of drug effect (up to seven days) and a seven-day latency period. Thus, the exposure status indicated the potential for a hospital admission at the case or control time to have resulted from the effects of PIM exposure.
Once the case and control details were finalized, conditional logistic regression models with robust analysis of variance were applied using the SAS 9.2 PHREG procedure, with the COVS option and stratification based on a unique identifier for each subject. The OR of primary interest was derived from the coefficient of the cross-product between exposure and the binary index/reference indicator. 18 The adjusted model controlled for all health and drug consumption indicators mentioned earlier.
This analysis was performed separately for each aged care group (i.e. highlevel nursing home residents versus other elderly). The initial models used a dichotomous variable as the PIM exposure measure, but subsequent analyses substituted this variable with the number of different PIMs and the number of PIM daily doses taken in the three-month period prior to the case or control time to enable the examination of associations related to PIM polypharmacy and dose-response, respectively.
PIM-related unplanned hospitalizations
Using the OR derived from the interaction between PIM exposure and the index/reference indicator, the attributable fraction (AF) of unplanned hospitalizations associated with PIMs within the exposed was calculated, where AF=(OR-1)/OR. An estimate of the number of unplanned hospital admissions attributed to PIMs was then derived as AF x count of exposed index subjects. [21] [22] [23] To further compare the unplanned hospitalization profile in the two groups counts of unplanned admissions attributed to PIMs in exposed patients; those not attributed to PIMs in the exposed; and those occurring in unexposed patients.
Results
In our population of 251,305 elderly people, 245,436 (97.7%) had either taken a PIM from the 'general' Beers list during 1993-2005 or a drug used to treat conditions similar to the indications for prescribing these PIMs. Of these, 187,616 (76.4%) had actually been prescribed a PIM, and 120,332 (49.0%) had hospital admissions that met the criteria for inclusion as 'index subjects'. Table 1 summarizes overall study results for both high-care nursing home residents and other elderly. Overall, 383,150 unplanned admissions ('index subjects') were included, 20,525 (5.4%) of which involved high-care nursing home residents. The proportion of male index subjects was much lower, the mean age higher, and the proportion exposed to a PIM at the time of admission higher in the high-level aged care group than in other WA elderly. For a detailed comparison between the two groups regarding exposure to specific PIMs upon admission, please refer to Table 2 .
Exposure to a PIM was associated with a significant increase in unplanned hospitalizations in both groups. Unadjusted results suggested a lower relative risk of PIM-related unplanned hospitalization in the high-care group. However, after adjusting for patients' health profile and medication intake over time, this difference was no longer evident (adjusted OR 1.21 (1.10-1.34) versus 1.19;
(1.16-1.21)).
Corresponding estimates of the proportion of unplanned hospitalizations attributed to PIMs in exposed index subjects were also similar in both groups ( Table 1 ).
The relative risk of unplanned hospitalization also rose in a similar manner in both groups with increasing counts of different PIMs taken over three months,
ORs for both suggesting a risk in those taking 10 different PIMs 5.1 times that of PIM-unexposed counterparts (Figure 1 ). However, high-care nursing home residents seemed affected to a greater extent by increasing PIM quantities than other elderly. For instance, high-level aged care residents taking 900 PIM daily doses over three months had a relative risk of unplanned hospitalization 4.85
(2.40-9.83) times that of high-care residents unexposed to PIMs, whereas the corresponding OR in other elderly was 2.10 (1.73-2.55) ( Figure 2 ).
Finally, nursing home residents receiving high-level care not only had higher overall rates of unplanned hospitalizations and of unplanned hospitalizations while exposed to PIMs than other WA elderly, they also had considerably higher rates of unplanned hospital admissions attributed to PIM exposure (3,951 versus 1,394 per 100,000 person-years) (Figure 3 ).
Discussion
This study examined the association between PIM exposure and unplanned hospitalizations in a large WA population aged ≥65 years, comparing high-care
nursing home residents with all other elderly people. Data linkage facilitated the establishment of a fairly comprehensive health profile for each individual, permitted extensive cross-validation of demographic details, and allowed the ascertainment of patients' drug exposure status upon admission.
Major findings
After adjusting for confounding factors (including health and medication profiles), the association between exposure to general Beers medications and unplanned hospitalizations was similar in both the high-care nursing home residents and other WA elderly. Our adjusted ORs for both groups suggested a likely increase in unplanned admissions around 20% in subjects exposed to PIMs. These results were similar to or slightly lower than those obtained in other comparable studies involving older people in nursing home (OR 1.27) 24 and community settings (OR range 1.62-1.78). [25] [26] [27] From our ORs, we deduced that 17.5% (8.9-25.2%) of unplanned hospitalizations in high-care nursing home residents were attributed to PIMs in exposed subjects, and 15.7% (13.7-17.6%) in other elderly.
Our results also suggested that the likelihood of unplanned hospitalization increases with the number of different PIMs and overall PIM quantity taken, in both groups of elderly. This is not surprising, given that polypharmacy and high medication intake are linked to an increased risk of adverse drug events. [1] [2] [3] In both groups, the risk of unplanned hospitalization increased five-fold when taking 10 different PIMs compared to none. However, the impact of PIM quantity on unplanned hospitalizations in nursing home residents seemed to be greater than in other elderly. For example, high-level aged care residents taking the equivalent of ten average daily doses of PIMs every day over three months (~900 daily doses) appeared to have nearly five times the risk of unplanned hospitalization of PIM-unexposed nursing home residents, whereas a similar comparison in other elderly yielded only a two-fold risk increase. One may speculate that perhaps nursing home residents were particularly sensitive to higher doses of PIMs due to their increased levels of physiological deterioration, which increased their susceptibility to adverse drug effects when taking high doses. More in-depth investigations beyond the scope of our study would be required to gain a better understanding of this apparent difference.
Despite similar overall relative risks of PIM-related unplanned hospitalizations in both groups of elderly, high-care nursing home residents had substantially higher rates of unplanned hospitalizations attributed to PIMs than other older people. This is likely due to their poorer health and thus, greater requirement for medications (including PIMs) and susceptibility to hospitalization. Our nursing home subjects' much higher rates of unplanned admissions, overall and while exposed to PIMs, support this premise.
Given the much smaller size of the high care group, the expectation that exposure to most individual PIMs would be low, and limitations in resources, we concentrated on associations that were related to overall PIM exposure in this study. However, the PIM exposure statistics from Table 2 suggest that further comparative analysis may be warranted for some individual PIMs in future, especially temazepam (sedative), digoxin (cardiac glycoside), and oxazepam (anxiolytic). These PIMs were highly prevalent in our index population, especially in subjects who were high-care nursing home residents.
Limitations
Despite an extensive clean-up and cross-validation process, made possible through data linkage, our research was subject to some data quality and availability issues, as per other studies involving administrative health data. In particular, our PBS data had some coverage limitations. It excluded drugs prescribed in public hospitals, over-the-counter medications, and prescriptions for which a pharmaceutical claim could not be made. 28 However, in our elderly population, most of whom would have had very low co-payment requirements, these coverage issues unlikely impacted on study results to any great extent, as most non-hospital scripts for medications of interest would have been recorded in this age group.
Furthermore, difficulties in the ascertainment of drug exposure at the specific times of interest were of concern, as no information was available on the daily dose specifically prescribed for each dispensed drug. Much attention was devoted to the derivation of exposure status from average recommended daily doses, but this could not have been completely accurate for every subject.
Assuming similar levels of exposure misclassification at both case and control times for each subject (i.e. non-differential measurement error), our estimated ORs may possibly have been attenuated slightly (i.e. pushed towards null) as a result. 29 This OR attenuation may, however, have been counter-balanced to some extent by an opposite effect stemming from residual time trend bias related to the case-time-control design. 18, 19, 30 To address this problem, we adjusted for each subject's health status and overall drug consumption over time using a number of relevant variables, in addition to the inclusion of matched reference subjects. Our prior work suggests that this approach improves internal validity. 31 Nonetheless, data limitations may have prevented us from fully adjusting for time-dependent confounders.
We also acknowledge that the aged care status criteria used to match index and reference subjects were imperfect. Since this variable changed over time,
we used people's status at 30 June of the index admission year for matching purposes. Although we did control further in the analysis for aged care status at the specific case and control times, our results may have been affected slightly by associated misclassification.
Conclusions
Our study not only provides further evidence in support of an increased risk of serious harm resulting from exposure to Beers medications in older people, but also refutes the hypothesis that high-level aged care residents have a higher subjects included all other elderly (i.e. those receiving low-level hostel or community aged care services and those living in a private home without any aged care support at that time). § Exposed index subjects were those who were taking ≥1 PIM immediately prior to hospital admission. ¶ 95% confidence interval shown in parentheses. 
